Back to Journals » Oncolytic Virotherapy » Volume 1

Oncolytic virotherapy for ovarian cancer

Authors Li, Tong, Rahman, Shepherd, McFadden G 

Received 4 May 2012

Accepted for publication 18 July 2012

Published 23 August 2012 Volume 2012:1 Pages 1—21


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Download Article [PDF] 

Shoudong Li,1 Jessica Tong,2,3 Masmudur M Rahman,1 Trevor G Shepherd,2,3 Grant McFadden1

1Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA; 2Department of Anatomy and Cell Biology, University of Western Ontario, London, Ontario, Canada; 3Translational Ovarian Cancer Research Program, London Health Sciences Centre, London, Ontario, Canada

Abstract: In the past two decades, more than 20 viruses with selective tropism for tumor cells have been developed as oncolytic viruses (OVs) for treatments of a variety of malignancies. Of these viruses, eleven have been tested in human ovarian cancer models in preclinical studies. So far, nine phase I or II clinical trials have been conducted or initiated using four different types of OVs in patients with recurrent ovarian cancers. In this article, we summarize the different OVs that are being assessed as therapeutics for ovarian cancer. We also present an overview of recent advances in identification of key genetic or immune-response pathways involved in tumorigenesis of ovarian cancer, which provides a better understanding of the tumor specificities and oncolytic properties of OVs. In addition, we discuss how next-generation OVs could be genetically modified or integrated into multimodality regimens to improve clinical outcomes based on recent advances in ovarian cancer biology.

Keywords: oncolytic virus, virotherapy, ovarian cancer, preclinical studies, clinical trial

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]